ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marsh, S.
Right arrow Articles by Beasley, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsh, S.
Right arrow Articles by Beasley, R.
Eur Respir J 2006; 28:883-884
Copyright ©ERS Journals Ltd 2006

Smoking and COPD: what really are the risks?

S. Marsh1, S. Aldington1, P. Shirtcliffe1, M. Weatherall2 and R. Beasley1,3

1 Medical Research Institute of New Zealand, and 2 Wellington School of Medicine & Health Sciences, Wellington, New Zealand. 3 University of Southampton, Southampton, UK.

To the Editors:

Chronic obstructive pulmonary disease (COPD) is rapidly becoming a global public health crisis, with around three million people predicted to die from the disease in 2006 1, 2. There is growing awareness of the increasing global burden of COPD not only in terms of mortality, but also its prevalence, morbidity and economic costs 2. In response to these concerns, there has been a renewed research effort to understand the causes of COPD and to develop public health and pharmacological interventions that may reduce the burden.

Smoking is recognised as the most important causative factor for COPD, with an individual's susceptibility being a continuous, rather than a categorical characteristic that can interact synergistically with other risk factors. There is now evidence that most smokers develop some respiratory impairment due to COPD 3. One of the most informative recent studies addressing this issue is the Obstructive Lung Disease in North Sweden (OLIN) study 4. From this cohort study, it was reported that ~50% of smokers eventually develop COPD, as defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2. This finding is of major clinical significance, in that it provides a scientific basis for the advice that can now be given to smokers that if they continue smoking lifelong, they have at least a one in two chance of developing COPD. Importantly, the study also provides evidence that the risk of developing COPD falls by about half with smoking cessation.

The OLIN study also allowed determination of the proportion of COPD cases that is due to smoking 4. Utilising the GOLD criteria for the diagnosis of COPD, the population attributable risk of COPD for smoking was 45% (95% confidence interval (CI) 29–58%) in the 46–77-yr age group. Utilising the British Thoracic Society criteria 5, which are considerably more stringent than the GOLD criteria for the diagnosis of COPD, the population attributable risk was 50% (95% CI 28–67%). This population attributable risk is considerably less than current dogma suggests, with a figure of 80–90% commonly quoted 68. A comparable population attributable risk of 44% (95% CI 38–50%) can be calculated from the third National Health and Nutrition Examination Survey (NHANES III) 9. However, this figure is qualified by the lack of post-bronchodilator lung function measurements in the NHANES III, which means that the COPD criteria employed were more inclusive of cases with asthma.

If only about half of all cases of COPD are due to smoking, what factors are responsible for the other half and what can be done to reduce their impact? It is not widely recognised that up to 20% of cases of COPD worldwide can be attributed to indoor air pollution from exposure to smoke from cooking and heating with biomass fuels in poorly ventilated dwellings 10, 11. This is likely to explain the similar prevalence of COPD in females and males in developing countries, despite markedly lower rates of smoking in females 2. Greater recognition of the role of indoor air pollution is a necessary prerequisite for the development of strategies to lessen its impact, and to reduce the occurrence of COPD.

A comparable example, which is amenable to public health and government interventions, is workplace exposure to a wide variety of dusts, chemicals and fumes. Given that up to 20% of cases of COPD may be attributed to occupational exposures 12, the potential benefit of preventive measures are apparent. As with indoor air pollution, the greatest burden of COPD due to occupational exposures is in the developing world. Other risk factors that could potentially be modified at an individual or population level are outdoor air pollution, marijuana smoking, chronic respiratory infection, diet, childhood asthma and factors associated with lung growth in utero and infancy.

We suggest that a greater understanding of the causation of chronic obstructive pulmonary disease is a research priority to provide the basis for the development of primary and secondary intervention programmes. This recommendation does not lessen the significance of tobacco smoking as the most important cause of chronic obstructive pulmonary disease, or the public health importance of measures to reduce tobacco consumption internationally. Smoking remains an important cause of global mortality, being accountable for around five million premature deaths in the world every year, including about one million due to chronic obstructive pulmonary disease 13.

REFERENCES

  1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;365:613–620.
  2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. www.goldcopd.com. Date last accessed: July 13 2006. Date last updated: 2005
  3. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006;367:1216–1219.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  4. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003;97:115–122.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  5. British Thoracic Society. Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52: Suppl. 5 S1–S28.[Medline] [Order article via Infotrieve]
  6. Calverley PMA, MacNee W, Pride NB, Rennard SI, eds. Chronic Obstructive Pulmonary Disease. 2nd Edn. London, Arnold, 2003
  7. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121: Suppl. 5 121S–126S.[Abstract/Free Full Text]
  8. US Surgeon General, ed. The Health Consequences of Smoking: Chronic Obstructive Lung Disease. Publ No. 84–50205. Washington DC, USDHHS, 1984
  9. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function mortality in the United States: data from the first National Health and Nutrition Examination Survey follow up study. Thorax 2003;58:388–393.[Abstract/Free Full Text]
  10. World Health Report 2002. Message from the Director-General, Dr GH Brundtland. Overview. Geneva, World Health Organization, 2002; pp. ix–xx
  11. World Health Report 2002. Message from the Director-General, Dr GH Brundtland. Quantifying selected major risks to health. Geneva, World Health Organization, 2002; pp. 68–76
  12. Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003;22:462–469.[Abstract/Free Full Text]
  13. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003;362:847–852.[CrossRef][ISI][Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
ThoraxHome page
J. Vestbo
COPD, diagrams and traditions: time to move on?
Thorax, September 1, 2008; 63(9): 755 - 756.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marsh, S.
Right arrow Articles by Beasley, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsh, S.
Right arrow Articles by Beasley, R.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS